abstract |
The present invention relates to a pharmaceutical composition comprising an antigen-binding protein that specifically binds to oncostatin M (OSM) and particularly human OSM (hOSM) and inhibits the binding of OSM to the gp130 receptor, said pharmaceutical composition As well as methods of administration of said pharmaceutical composition in the treatment of inflammatory or autoimmune disorders, in particular the treatment of systemic sclerosis. |